|By Business Wire||
|May 29, 2014 06:00 PM EDT||
Agilent Technologies Inc. (NYSE: A) today announced an agreement for global distribution of Cartagenia’s cloud-based software for copy number variation (CNV) analysis. This agreement will enable Agilent to sell usage-priced annual licenses for Cartagenia’s Bench Lab CNV module to small and medium-sized cytogenetic laboratories. The use-based licenses allow labs with limited budgets and little or no bioinformatics resources to gain access to a powerful interpretation support module to draft clinical grade reports.
“Cartagenia is pleased to work with Agilent on this distribution agreement of our Bench Lab CNV module,” said Herman Verrelst, chief executive officer, Cartagenia. “Patient-centric interpretation of microarray data can be greatly facilitated by adopting automated data analysis pipelines and workflows, increasing lab efficiency.”
“With expanded distribution capabilities, we can now reach small- to medium-sized labs more efficiently and provide them with our data analysis platform,” Verrelst added. “The CNV module is a proven platform, offers standardized workflows, and automated SOPs for fast turnaround times. Since it is a cloud-based platform, it allows for rapid installation, integration with legacy data, and provides labs with greater access to our product without adding bioinformatics resources.”
Cartagenia supplies interpretation support software, database systems and related services to genetic labs and clinicians, enabling them to perform clinically relevant analysis of genetic findings quickly and efficiently.
The Cartagenia Bench CNV platform is built in collaboration with genetics labs and clinical experts involved in routine medical practice. Because of this, Bench Lab CNV addresses the specific needs of genetic diagnostic labs and clinicians.
“Agilent is the first worldwide reseller to offer the Cartagenia Bench Lab CNV, and we are excited to provide this solution,” said Jacob Thaysen, Agilent’s vice president and general manager, Diagnostics and Genomics Group. “Labs with minimal software budget and resources can now afford to implement proven, standardized processes to analyze, interpret, and report their CGH data and generate precise draft lab reports with minimal disruption to their analysis workflow and staff.”
To learn more, please visit www.agilent.com/genomics/cartagenia.
Cartagenia Bench Lab CNV is built using a certified ISO13485 Quality Management System and is registered with the FDA as an exempt Class I Medical Device in the United States and as a Class I Medical Device in Europe in conformity with the essential requirements and provisions of the Council Directive 93/42/EEC concerning medical devices, and with the relevant harmonized standards EN ISO62304. www.cartagenia.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world’s premier measurement company and a technology leader in chemical analysis, life sciences, diagnostics, electronics and communications. The company’s 20,600 employees serve customers in more than 100 countries. Agilent had revenues of $6.8 billion in fiscal 2013. Information about Agilent is available at www.agilent.com.
On Sept. 19, 2013, Agilent announced plans to separate into two publicly traded companies through a tax-free spinoff of its electronic measurement business. The new company is named Keysight Technologies, Inc. The separation is expected to be completed in early November 2014.
Agilent Cytogenomics software is For Research Use Only. Not for use in diagnostic procedures.
NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Oct. 1, 2016 01:30 PM EDT Reads: 846
Oct. 1, 2016 01:00 PM EDT Reads: 5,185
Oct. 1, 2016 12:30 PM EDT Reads: 3,098
Oct. 1, 2016 12:30 PM EDT Reads: 5,528
Oct. 1, 2016 12:30 PM EDT Reads: 617
Oct. 1, 2016 12:30 PM EDT Reads: 2,329
Oct. 1, 2016 12:30 PM EDT Reads: 3,264
Oct. 1, 2016 12:30 PM EDT Reads: 609
Oct. 1, 2016 11:45 AM EDT Reads: 2,808
Oct. 1, 2016 11:30 AM EDT Reads: 1,330
Oct. 1, 2016 11:15 AM EDT Reads: 883
Oct. 1, 2016 10:45 AM EDT Reads: 628
Oct. 1, 2016 10:30 AM EDT Reads: 721
Oct. 1, 2016 10:30 AM EDT Reads: 1,729